- Biologic therapy is associated with a reduction in fatigue among patients with psoriasis, according to a systematic review and meta-analysis.
Why this matters
- Fatigue is a common problem in patients with psoriasis.
- Biologic treatment was associated with a reduction in fatigue compared with placebo (standardized mean difference, −0.40; P<.001>
- There was no evidence of effect differences between different biological agents.
- 8 randomized controlled trials (n=6033 patients) were included in the meta-analysis.
- Included studies used either the Short Form-36 Vitality Subscale or Functional Assessment of Chronic Illness Therapy-Fatigue to score fatigue.
- Biologic agents studied included infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), ustekinumab (Stelara), and guselkumab (Tremfya).
- Funding: Western Norway Regional Health Authority.
- Only PubMed was searched for relevant articles.
- No long-term analysis of fatigue (included studies assessed fatigue at or before 16 weeks).